Monday, January 27, 2025 4:52:21 PM
How likely is it that these options will fall in the money and be exercised by the time they expire?
IIRC, even the 2024 would need ~$9 to make it worthwhile. Lots of incentive.
11/20/2015: 110,000 shares, Exercise Price: $31.42, Expiration Date: 11/20/2025
11/18/2016: 120,000 shares, Exercise Price: $30.00, Expiration Date: 11/18/2026
11/17/2017: 100,000 shares, Exercise Price: $48.52, Expiration Date: 11/17/2027
11/16/2018: 68,000 shares, Exercise Price: $81.20, Expiration Date: 11/16/2028
11/18/2019: 110,000 shares, Exercise Price: $63.35, Expiration Date: 11/18/2029
11/20/2020: 101,062 shares, 6,738 shares, Exercise Price: $43.57, Expiration Date: 11/20/2030
11/19/2021: 74,112 shares, 33,688 shares, Exercise Price: $75.33, Expiration Date: 11/19/2031
11/23/2022: 58,625 shares, 75,375 shares, Exercise Price: $45.00, Expiration Date: 11/23/2032
11/22/2023: 49,500 shares, 214,500 shares, Exercise Price: $8.99, Expiration Date: 11/22/2033
IIRC, even the 2024 would need ~$9 to make it worthwhile. Lots of incentive.
11/20/2015: 110,000 shares, Exercise Price: $31.42, Expiration Date: 11/20/2025
11/18/2016: 120,000 shares, Exercise Price: $30.00, Expiration Date: 11/18/2026
11/17/2017: 100,000 shares, Exercise Price: $48.52, Expiration Date: 11/17/2027
11/16/2018: 68,000 shares, Exercise Price: $81.20, Expiration Date: 11/16/2028
11/18/2019: 110,000 shares, Exercise Price: $63.35, Expiration Date: 11/18/2029
11/20/2020: 101,062 shares, 6,738 shares, Exercise Price: $43.57, Expiration Date: 11/20/2030
11/19/2021: 74,112 shares, 33,688 shares, Exercise Price: $75.33, Expiration Date: 11/19/2031
11/23/2022: 58,625 shares, 75,375 shares, Exercise Price: $45.00, Expiration Date: 11/23/2032
11/22/2023: 49,500 shares, 214,500 shares, Exercise Price: $8.99, Expiration Date: 11/22/2033
Recent ENTA News
- Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria • Business Wire • 04/13/2026 11:00:00 AM
- Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 • Business Wire • 04/07/2026 11:00:00 AM
- Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) • Business Wire • 03/30/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:20:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:18:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:14:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:05:29 PM
- Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference • Business Wire • 03/03/2026 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/23/2026 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:31:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:29:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:28:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:27:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/11/2026 09:43:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:00:44 PM
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting • Business Wire • 02/10/2026 12:00:00 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 • Business Wire • 02/09/2026 09:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2026 09:10:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2026 09:05:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/20/2026 09:42:25 PM
